This year's growth is estimated at 2.6 percent, which can be compared with the significantly weaker forecast of 1.4 percent in August.
For 2027, the Danish government sees a slight slowdown to growth of 1.6 percent, partly because the Danish pharmaceutical industry is expected to grow more slowly.
According to the forecast, the outlook has cleared somewhat regarding the Trump administration's tariffs, and the Danish pharmaceutical industry is expected to keep production going and maintain export levels, according to the country's Ministry of Finance.
Novo Nordisk has faced headwinds this year due to cheaper versions of its best-selling weight loss and diabetes drugs Wegovy and Ozempic. As recently as November, the company lowered its full-year forecast for the fourth time this year, and the headwinds have raised concerns about mass layoffs and a broad economic downturn.
